Drug Profile


Alternative Names: Afema; CGS 16949; CGS 16949A; CGS 20287

Latest Information Update: 24 Nov 2000

Price : $50

At a glance

  • Originator Novartis
  • Class Antineoplastics; Imidazoles; Nitriles; Small molecules
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 24 Nov 2000 A study has been added to the Cancer therapeutic trials section
  • 25 Aug 1998 Profile reviewed
  • 03 Jul 1996 A study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top